scholarly journals Carotid Angioplasty and Stent Placement after EVA-3S Trial

Stroke ◽  
2007 ◽  
Vol 38 (6) ◽  
pp. 1993-1996 ◽  
Author(s):  
Adnan I. Qureshi
Keyword(s):  
Stent Placement ◽  
Carotid Angioplasty

scholarly journals Age differential between outcomes of carotid angioplasty and stent placement and carotid endarterectomy in general practice

2012 ◽  
Vol 55 (1) ◽  
pp. 72-78 ◽  
Author(s):  
Rakesh Khatri ◽  
Saqib A. Chaudhry ◽  
Gabriela Vazquez ◽  
Gustavo J. Rodriguez ◽  
Ameer E. Hassan ◽  
...  
Keyword(s):  
General Practice ◽  
Carotid Endarterectomy ◽  
Stent Placement ◽  
Carotid Angioplasty

Open-label Phase I Clinical Study to Assess the Safety of Intravenous Eptifibatide in Patients Undergoing Internal Carotid Artery Angioplasty and Stent Placement

Neurosurgery ◽  
2001 ◽  
Vol 48 (5) ◽  
pp. 998-1005 ◽  
Author(s):  
Adnan I. Qureshi ◽  
Zulfiqar Ali ◽  
M. Fareed K. Suri ◽  
Stanley H. Kim ◽  
Richard D. Fessler ◽  
...  
Keyword(s):  
Phase I ◽  
Stent Placement ◽  
Bleeding Complications ◽  
Study Patient ◽  
Carotid Angioplasty ◽  
Open Label ◽  
End Point ◽  
Open Label Phase ◽  
Ischemic Events ◽  
Neurointerventional Procedures

Abstract OBJECTIVE Eptifibatide, a competitive platelet glycoprotein IIb-IIIa receptor inhibitor with high selectivity and a short half-life, has been demonstrated to reduce the risk of ischemic events associated with coronary interventions. However, its role in neurointerventional procedures needs to be analyzed. We report the results of an open-label Phase I study to evaluate the safety of the use of eptifibatide during carotid angioplasty and stent placement. METHODS Each study patient received eptifibatide administered intravenously as a 135-μg/kg single-dose bolus, then a 0.5-μg/kg/min infusion for 20 to 24 hours during carotid angioplasty and stent placement. The primary efficacy end point was the 30-day composite occurrence of death, cerebral infarction, transient ischemic attack, and unplanned or urgent surgical intervention, thrombolysis, or subsequent percutaneous revascularization. The primary safety end point was bleeding. Bleeding complications were classified as major (hemoglobin decrease >5 g/dl), minor (hemoglobin decrease 3–5 g/dl), or insignificant. RESULTS Ten patients (mean age, 73 yr; four men) were treated by use of the study protocol. One patient developed a minor stroke postprocedurally (National Institutes of Health Stroke Scale score of 21 at 24 h that improved to 1 at 7 d). Three patients underwent scheduled coronary artery bypass graft surgery 4 to 12 days after undergoing carotid angioplasty and stent placement. At 1-month follow-up, no new ischemic events were observed. Major or minor bleeding was not observed in any patient. Insignificant bleeding was observed in two patients. CONCLUSION The use of eptifibatide as an adjunct to carotid angioplasty and stent placement seems to be safe. Further studies are required to analyze the effectiveness and role of eptifibatide in neurointerventional procedures.

Abstract TP154: Device Malfunction Related Adverse Events in Patients Undergoing Carotid Angioplasty and Stent Placement: An analysis of the FDA Manufacturer and User Facility Device Experience Database

Stroke ◽  
2013 ◽  
Vol 44 (suppl_1) ◽  
Author(s):  
Hunar S Kainth ◽  
Daraspreet S Kainth ◽  
Waqas I Gilani ◽  
Sarwat I Gilani ◽  
Malik M Adil ◽  
...  
Keyword(s):  
United States ◽  
Carotid Artery ◽  
Adverse Events ◽  
Stent Placement ◽  
Large Scale ◽  
The United States ◽  
Carotid Angioplasty ◽  
Carotid Stent ◽  
Device Malfunction ◽  
User Facility

Background: Carotid angioplasty and stenting (CAS) has emerged as a less invasive treatment alternative to carotid endarterectomy and the frequency of CAS is increasing. A large scale analysis of the device malfunction related adverse events associated with carotid stenting has not previously been undertaken. Methods: Adverse events reported to the United States FDA Manufacturer and User Facility Device Experience were analyzed. This data includes voluntary reporting of adverse events related to medical device use. We analyzed the characteristics of device related adverse events which included hypotension, bradycardia, hyperperfusion syndrome, transient ischemic attack (TIA), stroke, carotid artery spasm, myocardial infarction, cardiac arrest, and vessel dissection from 2010 to 2012 in the United States. Results: From 2010 to 2012, there were a total of 1211 adverse events reported to the FDA related to CAS. The most common adverse event was stroke, which represented 39.3% of the clinical adverse events. Adverse device deployment was most commonly affected by intraprocedural malfunction of the stent, which occurred in 22.0% of reported events, followed by incomplete coverage by the stent requiring a second stent, 15.5% of events. In addition, vessel tortuosity, 11.0% of events, and vessel calcification, 4.5%, played a role in adversely affecting stent deployment. The stents most commonly involved in intraprocedural malfunction were the Carotid Wall Monorail stent and the Acculink carotid stent, which represented 29.5% and 30.8% of the failures respectively. The clinical events associated with device malfunction were stroke (n=464), TIA (n=186), carotid artery spasm (n=30), and carotid dissection (n=8). Conclusions: This is the first large scale study to report on the device malfunction related adverse events associated with carotid stent placement. The most common device complication relates to intraprocedural malfunction of the stent, which represents 22% of reported failures.

New Brain Lesions at MR Imaging after Carotid Angioplasty and Stent Placement

Radiology ◽  
2002 ◽  
Vol 224 (2) ◽  
pp. 361-365 ◽  
Author(s):  
Hans P. M. van Heesewijk ◽  
Jan Albert Vos ◽  
Elisabeth S. Louwerse ◽  
Jos C. van den Berg ◽  
Timotheus T. C. Overtoom ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Stent Placement ◽  
Brain Lesions ◽  
Carotid Angioplasty

Quality Improvement Guidelines for the Performance of Cervical Carotid Angioplasty and Stent Placement

2003 ◽  
Vol 14 (9) ◽  
pp. S321-S335 ◽  
Author(s):  
John D. Barr ◽  
John J. Connors ◽  
David Sacks ◽  
John F. Cardella ◽  
Joan C. Wojak ◽  
...  
Keyword(s):  
Quality Improvement ◽  
Stent Placement ◽  
Carotid Angioplasty

Carotid angioplasty and stent placement for restenosis after endarterectomy

2007 ◽  
Vol 49 (4) ◽  
pp. 357-364 ◽  
Author(s):  
Yasha Kadkhodayan ◽  
Christopher J. Moran ◽  
Colin P. Derdeyn ◽  
DeWitte T. Cross
Keyword(s):  
Stent Placement ◽  
Carotid Angioplasty

Abstract P516: A Comparison of Transradial and Transfemoral Approaches for Performance of Carotid Angioplasty and Stent Placement

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Nitish Kumar ◽  
Sachin Bhagavan ◽  
Vamshi Balasetti ◽  
Tariq Hamid ◽  
Muhammad F Ishfaq ◽  
...  
Keyword(s):  
Intracranial Hemorrhage ◽  
Stent Placement ◽  
Technical Failure ◽  
Carotid Angioplasty ◽  
Transfemoral Approach ◽  
Transradial Approach ◽  
Clinical Endpoints ◽  
Post Procedure ◽  
Hemorrhagic Complications ◽  
Neurointerventional Procedures

Context: Over the past few decades, transradial access has been increasingly utilized for neurointerventional procedures including carotid angioplasty and stent placement (CAS). Objective: To compare the outcomes of CAS performed via transradial approach with those performed using transfemoral approach within the same institution. Methods: We analyzed all the elective CAS procedures performed at our institute in the last 48 months and divided the procedures based on initial approach (transradial or transfemoral). Both approaches were used by same interventionalists to minimize inter-operator variability. We compared the rates of technical failure; hemorrhagic complications classified as major (hemoglobin decrease >5 g/dL or intracranial hemorrhage with deficits), minor (hemoglobin decreases 3-5 g/dL or intracranial hemorrhage without residual deficits), or insignificant; and any stroke and/or death within 1-month post procedure. Results: A total of 120 elective CAS procedures were performed at our institution; 84 patients (70%) were initiated as transfemoral and 36 patients (30%) were initiated as transradial approach. There were 6 (16%) CAS procedures initiated as trans-radial but later switched to transfemoral due to anatomical and/or technical difficulties. Similarly, 1(1.2%) procedure was switched to transradial from transfemoral. So finally, 89 (74%) patients had transfemoral approach and 31 (26%) patients had transradial approach to CAS. The median age was similar between the two groups (66.5 years versus 67.3 years).The rates of major hemorrhagic complications were 2 (2.2 %) and 0 (0%) in CAS performed using tranfemoral and tranradial approaches, respectively. The rate of any stroke and/or death within 30 days post procedure was 5 (5.6 %) and 1 (3.2 %) in CAS performed using transfemoral and transradial approaches, respectively.The median fluoroscopy time was 36.1 minutes and 34.4 minutes using transfemoral and transfemoral approaches, respectively (p =0.72). Conclusions: Transradial approach is comparable to transfemoral approach for performance of CAS in regard to clinical endpoints although the rates of technical failure remain relatively high in patients in whom CAS was initiated from transradial approach.

Sign in / Sign up

Export Citation Format

Share Document